Search Results for author: Yuta Hozumi

Found 12 papers, 4 papers with code

Multiscale differential geometry learning of networks with applications to single-cell RNA sequencing data

1 code implementation15 Dec 2023 Hongsong Feng, Sean Cottrell, Yuta Hozumi, Guo-Wei Wei

Single-cell RNA sequencing (scRNA-seq) has emerged as a transformative technology, offering unparalleled insights into the intricate landscape of cellular diversity and gene expression dynamics.

Analyzing Single Cell RNA Sequencing with Topological Nonnegative Matrix Factorization

1 code implementation24 Oct 2023 Yuta Hozumi, Guo-Wei Wei

Single-cell RNA sequencing (scRNA-seq) is a relatively new technology that has stimulated enormous interest in statistics, data science, and computational biology due to the high dimensionality, complexity, and large scale associated with scRNA-seq data.

K-Nearest-Neighbors Induced Topological PCA for scRNA Sequence Data Analysis

no code implementations23 Oct 2023 Sean Cottrell, Yuta Hozumi, Guo-Wei Wei

We further introduce a k-Nearest-Neighbor (kNN) persistent Laplacian technique to improve the robustness of our persistent Laplacian method.

Dimensionality Reduction feature selection

Analyzing scRNA-seq data by CCP-assisted UMAP and t-SNE

1 code implementation23 Jun 2023 Yuta Hozumi, Gu-Wei Wei

Single-cell RNA sequencing (scRNA-seq) is widely used to reveal heterogeneity in cells, which has given us insights into cell-cell communication, cell differentiation, and differential gene expression.

Dimensionality Reduction feature selection

Emerging dominant SARS-CoV-2 variants

no code implementations18 Oct 2022 Jiahui Chen, Rui Wang, Yuta Hozumi, Gengzhuo Liu, Yuchi Qiu, Xiaoqi Wei, Guo-Wei Wei

Accurate and reliable forecasting of emerging dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants enables policymakers and vaccine makers to get prepared for future waves of infections.

CCP: Correlated Clustering and Projection for Dimensionality Reduction

2 code implementations8 Jun 2022 Yuta Hozumi, Rui Wang, Guo-Wei Wei

Most dimensionality reduction methods employ frequency domain representations obtained from matrix diagonalization and may not be efficient for large datasets with relatively high intrinsic dimensions.

Clustering Dimensionality Reduction

Emerging vaccine-breakthrough SARS-CoV-2 variants

no code implementations9 Sep 2021 Rui Wang, Jiahui Chen, Yuta Hozumi, Changchuan Yin, Guo-Wei Wei

The molecular mechanism underlying such surge is elusive due to 4, 653 non-degenerate mutations on the spike protein, which is the target of most COVID-19 vaccines.

Topological Data Analysis

Host immune response driving SARS-CoV-2 evolution

no code implementations17 Aug 2020 Rui Wang, Yuta Hozumi, Yong-Hui Zheng, Changchuan Yin, Guo-Wei Wei

Additionally, we show that children under age five and the elderly may be at high risk from COVID-19 because of their overreacting to the viral infection.

Characterizing SARS-CoV-2 mutations in the United States

no code implementations24 Jul 2020 Rui Wang, Jiahui Chen, Kaifu Gao, Yuta Hozumi, Changchuan Yin, Guo-Wei Wei

Using genotyping, sequence-alignment, time-evolution, $k$-means clustering, protein-folding stability, algebraic topology, and network theory, we reveal that the US SARS-CoV-2 has four substrains and five top US SARS-CoV-2 mutations were first detected in China (2 cases), Singapore (2 cases), and the United Kingdom (1 case).

Protein Folding

Decoding asymptomatic COVID-19 infection and transmission

no code implementations2 Jul 2020 Rui Wang, Yuta Hozumi, Changchuan Yin, Guo-Wei Wei

By analyzing the distribution of 11083G>T in various countries, we unveil that 11083G>T may correlate with the hypotoxicity of SARS-CoV-2.

Topological Data Analysis

Mutations on COVID-19 diagnostic targets

no code implementations5 May 2020 Rui Wang, Yuta Hozumi, Changchuan Yin, Guo-Wei Wei

Effective, sensitive, and reliable diagnostic reagents are of paramount importance for combating the ongoing coronavirus disease 2019 (COVID-19) pandemic at a time there is no preventive vaccine nor specific drug available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Decoding SARS-CoV-2 transmission, evolution and ramification on COVID-19 diagnosis, vaccine, and medicine

no code implementations29 Apr 2020 Rui Wang, Yuta Hozumi, Changchuan Yin, Guo-Wei Wei

Tremendous effort has been given to the development of diagnostic tests, preventive vaccines, and therapeutic medicines for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

COVID-19 Diagnosis

Cannot find the paper you are looking for? You can Submit a new open access paper.